Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hvidovre University Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Glucagon-like peptide-1(GLP-1) is secreted during a meal and increases glucose induced insulin secretion. The enzyme dipeptidyl peptidase 4(DPP-4) cleaves intact GLP-1 within minutes and DPP-4 inhibitors are therefore used for treatment of diabetic hyperglycemia. A few animal studies have implicated the enzyme neutral endopeptidase 24.11 (24.11) in the degradation of GLP-1 but if this is the case in humans with type 2 diabetes is unknown.
We therefore administered a NEP inhibitor, 194mg sacubitril, a DPP-4 inhibitor (sitagliptin 100mg the night before and 100mg 2 hours before), both, or placebo, to patients with type 2 diabetes during a standardized meal and measured plasma concentrations of GLP-1
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Participants are subjected to a standardized meal |
|
| Entrestro | Active Comparator | 194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal |
|
| Sitagliptin | Active Comparator | 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal |
|
| Entrestro + sitagliptin | Active Comparator | 194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal |
|
| Valsartan | Active Comparator | 206mg valsartan as one single dose followed by a standardized meal |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Entresto | Drug | Single dose administration of entresto |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Blood Glucose | Plasma Concentrations of glucose | 3 hours after treatment ( during the subsequent standardized meal) |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma Concentrations of GLP-1 | 3 hours after treatment ( during the subsequent standardized meal) | |
| Plasma Concentrations of GIP | 3 hours after treatment ( during the subsequent standardized meal) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hvidovre Hospital | Hvidovre | RegionH | 2650 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35676803 | Derived | Wewer Albrechtsen NJ, Moller A, Martinussen C, Gluud LL, Rashu EB, Richter MM, Plomgaard P, Goetze JP, Kjeldsen S, Hansen LH, Gustafsson F, Deacon CF, Holst JJ, Madsbad S, Bojsen-Moller KN. Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. Diabetes Obes Metab. 2022 Oct;24(10):2017-2026. doi: 10.1111/dom.14789. Epub 2022 Jul 21. |
Not provided
Not provided
Undecided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C549068 | sacubitril and valsartan sodium hydrate drug combination |
| D000068900 | Sitagliptin Phosphate |
| D000068756 | Valsartan |
| ID | Term |
|---|---|
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sitagliptin |
| Drug |
Single dose administration of sitagliptin |
|
| Valsartan | Drug | single doses administration of valsartan |
|
| Placebo | Drug | placebo day |
|
| Plasma Concentrations of Glucagon | 3 hours after treatment ( during the subsequent standardized meal) |
| Plasma Concentrations of Insulin | 3 hours after treatment ( during the subsequent standardized meal) |
| Plasma Concentrations of C-Peptide | 3 hours after treatment ( during the subsequent standardized meal) |
| Plasma Concentrations of Amino Acids | 3 hours after treatment ( during the subsequent standardized meal) |
| D011719 |
| Pyrazines |
| D013777 | Tetrazoles |
| D014633 | Valine |
| D000597 | Amino Acids, Branched-Chain |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
| D000601 | Amino Acids, Essential |